The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study-Reference-Cited by-同舟云学术

The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study

Published:2017-11 Issue:414 Volume:9 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Kiessling Peter¹^ORCID,Lledo-Garcia Rocio²^ORCID,Watanabe Shikiko³,Langdon Grant⁴,Tran Diep²,Bari Muhammad²,Christodoulou Louis²,Jones Emma⁵,Price Graham²^ORCID,Smith Bryan²,Brennan Frank²,White Ian²^ORCID,Jolles Stephen⁶^ORCID

Affiliation:

1. UCB Pharma, 40789 Monheim, Germany.

2. UCB Pharma, Slough SL1 3WE, UK.

3. UCB Pharma, Braine, 1420 Braine-l’Alleud, Belgium.

4. PTx Solutions Ltd., London, UK.

5. Veramed Ltd., Twickenham TW1 3QS, UK.

6. Department of Immunology, University Hospital of Wales, Cardiff CF14 4XW, UK.

Abstract

A first-in-human study of rozanolixizumab (UCB7665), an antihuman FcRn monoclonal antibody for IgG autoantibody-mediated diseases, is reported.

Funder

UCB Pharma

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference41 articles.

1. Steroids and immunosuppressant drugs in myasthenia gravis

2. Update on myasthenia gravis

3. Powikłania u chorych leczonych metodą plazmaferezy na oddziale intensywnej terapii

4. Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence

5. The Production Processes and Biological Effects of Intravenous Immunoglobulin

Cited by 155 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Food and Drug Administration (FDA) Approvals of Biological Drugs in 2023;Biomedicines;2024-09-02

2. Targeted Treatments for Myasthenia Gravis in Children and Adolescents;Pediatric Drugs;2024-08-28

3. Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Neonatal Fc Receptor Blocker, in Healthy Japanese Volunteers;Clinical Drug Investigation;2024-07-29

4. Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). I. Drugs in preclinical and early clinical development;Epilepsia;2024-07-15

5. Rozanolixizumab in generalized myasthenia gravis: a profile of its use;Drugs & Therapy Perspectives;2024-06